Press Releases

May 22, 2019
Bicycle Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 22, 2019-- Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) product platform, today announced the pricing of its initial public offering
May 09, 2019
Bicycle Therapeutics Strengthens Clinical Team to Advance Expanding Pipeline
CAMBRIDGE, U.K., and BOSTON, Mass., May 9, 2019 –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) product platform, today announced two senior appointments to facilitate its expanding and advancing
Mar 29, 2019
Bicycle Therapeutics to Present Preclinical Data on EphA2 and Nectin-4 Bicycle Toxin Conjugate Programs, as well as a CD137 Immune Oncology Program, at the American Association for Cancer Research Annual Meeting
CAMBRIDGE, U.K., and BOSTON, Mass., March 29, 2019  –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) product platform, announced today that Bicycle scientists have been selected to present two oral
Displaying 1 - 10 of 13